|
|
Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine : results of the randomized, placebo-controlled, phase 3b FOCUS study |
|---|---|
| Author: | MaassenVanDenBrink, Antoinette1; Terwindt, Gisela M.2; Cohen, Joshua M.3; |
| Organizations: |
1Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus University Medical Center Rotterdam, P.O. Box 2040, 3000, CA, Rotterdam, The Netherlands 2Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands 3Teva Pharmaceutical Products R&D, Inc., PA, West Chester, USA
4Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands
5Research Unit of Clinical Neuroscience, University of Oulu and Medical Research Center, Oulu University Hospital, Oulu, Finland |
| Format: | article |
| Version: | published version |
| Access: | open |
| Online Access: | PDF Full Text (PDF, 1.3 MB) |
| Persistent link: | http://urn.fi/urn:nbn:fi-fe2022020918380 |
| Language: | English |
| Published: |
Springer Nature,
2021
|
| Publish Date: | 2022-02-09 |
| Description: |
AbstractBackground: Migraine prevalence is age and sex dependent, predominating in women in early and middle adulthood; however, migraine also represents a substantial burden for men and adults of all ages. Thus, understanding this burden and the efficacy of migraine preventive medications in both sexes and across age groups is critical. The randomized, placebo-controlled, double-blind, phase 3b FOCUS study demonstrated the safety and efficacy of fremanezumab, a fully humanized monoclonal antibody (IgG2∆a) that selectively targets calcitonin gene-related peptide as a migraine preventive treatment for individuals with migraine and prior inadequate response to 2 to 4 migraine preventive medication classes. Here, we assessed the efficacy of fremanezumab in participants from FOCUS subgrouped by age (18–45 years and > 45 years) and sex. Methods: In the FOCUS study, eligible participants were randomized (1:1:1) to 12 weeks of double-blind treatment with quarterly fremanezumab, monthly fremanezumab, or matched monthly placebo. In this post hoc analysis, we evaluated changes from baseline in monthly migraine days (primary endpoint of FOCUS) and other secondary and exploratory efficacy outcomes in prespecified age (18–45 and > 45 years) and sex subgroups. Results: The modified intention-to-treat population (received ≥ 1 dose of study drug and had ≥ 10 days of postbaseline efficacy assessments for the primary endpoint) totaled 837 participants (18–45 years, n = 373; > 45 years, n = 464; male, n = 138; female, n = 699). Consistent reductions in monthly average number of migraine days during 12 weeks were observed, regardless of age (18–45 years: quarterly fremanezumab, − 4.1 days; monthly fremanezumab, − 4.7 days; placebo, − 0.9 days; P < 0.001; > 45 years: quarterly fremanezumab, − 3.6 days; monthly fremanezumab, − 3.7 days; placebo, − 0.3 days; P < 0.001) and sex (male: quarterly fremanezumab, − 4.1 days; monthly fremanezumab, − 4.6 days; placebo, − 0.3 days; P < 0.001; female: quarterly fremanezumab, − 3.6 days; monthly fremanezumab, − 3.9 days; placebo, − 0.6 days;P < 0.001). Fremanezumab also reduced monthly headache days of at least moderate severity, monthly days of acute medication use, and improved Migraine Disability Assessment scores across subgroups. Conclusions: These results demonstrate the efficacy of fremanezumab in patients with difficult-to-treat migraine for reducing migraine and headache days, acute medication use, and disability, regardless of age or sex. Trial registration: ClinicalTrials.gov Identifier NCT03308968 (FOCUS), registered October 13, 2017. see all
|
| Series: |
Journal of headache and pain |
| ISSN: | 1129-2369 |
| ISSN-E: | 1129-2377 |
| ISSN-L: | 1129-2369 |
| Volume: | 22 |
| Issue: | 1 |
| Article number: | 152 |
| DOI: | 10.1186/s10194-021-01336-1 |
| OADOI: | https://oadoi.org/10.1186/s10194-021-01336-1 |
| Type of Publication: |
A1 Journal article – refereed |
| Field of Science: |
3124 Neurology and psychiatry |
| Subjects: | |
| Funding: |
The FOCUS study (ClinicalTrials.gov Identifier:NCT03308968) and this post hoc analysis were funded by Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA. |
| Copyright information: |
© The Author(s). 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
|
https://creativecommons.org/licenses/by/4.0/ |